Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2293-2306

  Xiang, Yan ^a   Stine, Zachary E ^a   Xia, Jinsong ^a   Lu, Yunqi ^a   O'Connor, Roddy S ^b   Altman, Brian J ^a   Hsieh, Annie L ^a   Gouw, Arvin M ^a   Thomas, Ajit G ^c   Gao, Ping ^d   Sun, Linchong ^d   Song, Libing ^e   Yan, Benedict ^f   Slusher, Barbara S ^c,g   Zhuo, Jingli ^h   Ooi, London L ^h,i   Lee, Caroline G L ^f,j,k   Mancuso, Anthony ^a,b   McCallion, Andrew S ^l   Le, Anne ^g   Milone, Michael C ^b   Rayport, Stephen ^m   Felsher, Dean W ⁿ   Dang, Chi V ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DIVISION OF MEDICAL ONCOLOGY   (Singapore)

ⁱ SINGAPORE GENERAL HOSPITAL   (Singapore)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k DUKE NUS MEDICAL SCHOOL   (Singapore)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIS 2 (5 PHENYLACETAMIDO 1,3,4 THIADIAZOL 2 YL)ETHYL SULFIDE; ENZYME INHIBITOR; GLUTAMINASE; MESSENGER RNA; SULFIDE; UNCLASSIFIED DRUG; BIS-2-(5-PHENYLACETAMIDO-1,2,4-THIADIAZOL-2-YL)ETHYL SULFIDE; THIADIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B-CELL LYMPHOMA CELL LINE; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; DNA FRAGMENTATION; DNA REPLICATION; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LYMPHOMA CELL LINE; MALE; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; MISSENSE MUTATION; PATHOLOGY; TRANSGENIC MOUSE; XENOGRAFT;

AMINO ACID SUBSTITUTION; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINASE; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MUTATION, MISSENSE; NEOPLASM TRANSPLANTATION; SULFIDES; THIADIAZOLES;

EID: 84930392977     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75836     Document Type: Article

References (62)

1. Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3): 297-308.
2. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. Metabolic regulation by p53 family members. Cell Metab. 2013;18(5): 617-633.
3. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2): 85-95.
4. Dang CV. MYC on the path to cancer. Cell. 2012;149(1): 22-35.
5. Cantor JR, Sabatini DM. Cancer cell metabolism: One hallmark, many faces. Cancer Discov. 2012;2(10): 881-898.
6. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: Cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9): 3678-3684.
7. Altman BJ, Dang CV. Normal and cancer cell metabolism: Lymphocytes and lymphoma. FEBS J. 2012;279(15): 2598-2609.
8. DeBerardinis RJ, et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104(49): 19345-19350.
9. Le A, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15(1): 110-121.
10. Liu W, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A. 2012;109(23): 8983-8988.
11. Mullen AR, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481(7381): 385-388.
12. Wise DR, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48): 18782-18787.
13. Gao P, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239): 762-765.
14. Suzuki S, et al. Phosphate-Activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010;107(16): 7461-7466.
15. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010;107(16): 7455-7460.
16. Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4): 890-901.
17. Seltzer MJ, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70(22): 8981-8987.
18. Shukla K, et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido- 1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem. 2012;55(23): 10551-10563.
19. Wang JB, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18(3): 207-219.
20. Vander Heiden MG. Exploiting tumor metabolism: Challenges for clinical translation. J Clin Invest. 2013;123(9): 3648-3651.
21. Chandel NS. Navigating Metabolism. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 2014.
22. Xiang L, et al. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim Biophys Acta. 2013;1833(12): 2996-3005.
23. Giacobbe A, et al. p63 regulates glutaminase 2 expression. Cell Cycle. 2013;12(9): 1395-1405.
24. Ferreira AP, et al. Active glutaminase C selfassembles into a supratetrameric oligomer that can be disrupted by an allosteric inhibitor. J Biol Chem. 2013;288(39): 28009-28020.
25. Qie S, Chu C, Li W, Wang C, Sang N. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J Cell Biochem. 2014;115(3): 498-509.
26. van den Heuvel AP, Jing J, Wooster RF, Bachman KE. Analysis of glutamine dependency in nonsmall cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol Ther. 2012;13(12): 1185-1194.
27. Szeliga M, Bogacinska-Karas M, Rozycka A, Hilgier W, Marquez J, Albrecht J. Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells. Tumour Biol. 2013;35(3): 1855-1862.
28. Rajagopalan KN, DeBerardinis RJ. Role of glutamine in cancer: Therapeutic and imaging implications. J Nucl Med. 2011;52(7): 1005-1008.
29. Shapiro RA, Clark VM, Curthoys NP. Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site. J Biol Chem. 1979;254(8): 2835-2838.
30. Thornburg JM, et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 2008;10(5): R84.
31. DaVanzo JP, Kang L, Ruckart R, Daugherty M. Inhibition of pyridoxal phosphokinase by aminooxyacetic acid. Biochem Pharmacol. 1966;15(1): 124-126.
32. Robinson MM, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5- phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J. 2007;406(3): 407-414.
33. DeLaBarre B, et al. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry. 2011;50(50): 10764-10770.
34. Thangavelu K, et al. Structural basis for the allosteric inhibitory mechanism of human kidneytype glutaminase (KGA) and its regulation by Raf- Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A. 2012;109(20): 7705-7710.
35. Stalnecker CA, et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc Natl Acad Sci U S A. 2015;112(2): 394-399.
36. Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol. 2014;42(4): 247-251.
37. Wang R, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35(6): 871-882.
38. Macintyre AN, Rathmell JC. Activated lymphocytes as a metabolic model for carcinogenesis. Cancer Metab. 2013;1(1): 5.
39. Ko YH, et al. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: Implications for preventing chemotherapy resistance. Cancer Biol Ther. 2011;12(12): 1085-1097.
40. Beer S, et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol. 2004;2(11): E332.
41. Shachaf CM, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431(7012): 1112-1117.
42. Yuneva MO, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15(2): 157-170.
43. Hu S, et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab. 2011;14(1): 131-142.
44. Masson J, et al. Mice lacking brain/kidney phosphate-Activated glutaminase have impaired glutamatergic synaptic transmission, altered breathing, disorganized goal-directed behavior and die shortly after birth. J Neurosci. 2006;26(17): 4660-4671.
45. Gaisler-Salomon I, et al. Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: Relevance to schizophrenia. Neuropsychopharmacology. 2009;34(10): 2305-2322.
46. Schuhmacher M, et al. Control of cell growth by c-Myc in the absence of cell division. Curr Biol. 1999;9(21): 1255-1258.
47. Billiard J, et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab. 2013;1(1): 19.
48. Morcos PA, Li Y, Jiang S. Vivo-Morpholinos: A non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques. 2008;45(6): 613-614.
49. Zammarchi F, et al. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A. 2011;108(43): 17779-17784.
50. Gaglio D, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7: 523.
51. Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One. 2009;4(3): E4715.
52. Weinberg F, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010;107(19): 8788-8793.
53. Fendt SM, et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013;73(14): 4429-4438.
54. Terunuma A, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014;124(1): 398-412.
55. DiNardo CD, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121(24): 4917-4924.
56. Wang JH, et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci U S A. 2013;110(42): 17017-17022.
57. Yustein JT, Dang CV. Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol. 2007;14(4): 375-381.
58. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011;18(3): 219-228.
59. Puchades-Carrasco L, et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res. 2013;19(17): 4770-4779.
60. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002;295(5556): 868-872.
61. Chang TC, et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A. 2009;106(9): 3384-3389.
62. Engler JA, Gottesman JM, Harkins JC, Urazaev AK, Lieberman EM, Grossfeld RM. Properties of glutaminase of crayfish CNS: Implications for axon-glia signaling. Neuroscience. 2002;114(3): 699-705.